AmericanPeptide
Catalog/Tesamorelin + Ipamorelin

Tesamorelin + Ipamorelin

Also known as Tesamorelin/Ipamorelin · Tesa Ipa

A GH-secretagogue pairing built on an FDA-approved GHRH analog (Tesamorelin) plus a selective secretagogue (Ipamorelin).

Research refreshed

Overview

A combination of Tesamorelin — a stabilized GHRH analog FDA-approved for HIV-associated lipodystrophy — with Ipamorelin, a selective ghrelin-receptor secretagogue. It applies the same two-receptor logic as the CJC-1295 + Ipamorelin pairing, but uses a GHRH analog that has cleared clinical trials and carries an approved indication. The blend itself is a research combination: Tesamorelin is approved as a single agent, not in combination with Ipamorelin, and the mixture has no dedicated trial.

Background

This pairing is the “clinical-grade GHRH” version of the GHRH-plus-secretagogue stack. Tesamorelin is a GHRH analog with real trial data and an FDA approval for reducing visceral fat in HIV lipodystrophy; Ipamorelin adds a selective ghrelin-receptor signal on top. The two receptors are distinct, which is the basis for combining them.

The approval belongs to Tesamorelin alone. There is no trial of the Tesamorelin + Ipamorelin combination, so the blend inherits Tesamorelin’s evidence only for Tesamorelin, and Ipamorelin remains an unapproved research peptide. This page is a research reference, not a protocol.

Mechanism

Tesamorelin: GHRH-receptor agonism (stabilized against DPP-4) driving GH synthesis and release, with documented visceral-fat reduction. Ipamorelin: selective GHS-R1a agonism amplifying the GH pulse. Dual-pathway stimulation is studied for a larger pulse than either alone.

Key research findings

  • Approved GHRH component — Tesamorelin is FDA-approved (as a single agent) for HIV-associated lipodystrophy, unusual among secretagogue-blend components.
  • Two-receptor design — GHRH (Tesamorelin) plus GHS-R (Ipamorelin) stimulation studied for a larger GH pulse.
  • Blend is unstudied — the combination itself has no dedicated trial; the approval covers Tesamorelin alone.
  • Ipamorelin not approved — the secretagogue component is a research peptide.

How Tesamorelin + Ipamorelin is made

Behind every vial of Tesamorelin + Ipamorelin is the same exacting pipeline every research peptide runs — but the chemistry plays out differently for this molecule. Here is how Tesamorelin + Ipamorelin, specifically, is brought into being.

  1. On paper first

    Tesamorelin + Ipamorelin begins not as a powder but as a specification. Before a single bond is made, the target sequence, salt form, and purity threshold are written down as the contract the finished material must meet.

  2. Built residue by residue

    Tesamorelin + Ipamorelin is assembled by solid-phase peptide synthesis — the chain grows one protected residue at a time on resin, and what you fail to build cleanly here you pay to remove later.

  3. Purity is won here

    The crude mixture — Tesamorelin + Ipamorelin plus its deletions and side products — is then separated on preparative HPLC, and where the cut is taken decides the difference between a genuinely pure peptide and a barely-passable one.

  4. Proven, then protected

    A real batch of Tesamorelin + Ipamorelin proves itself: identity confirmed by mass spectrometry, purity read directly off an analytical HPLC trace, water and counterion content measured. That batch-specific certificate of analysis is the only honest way to know what is actually in a vial of Tesamorelin + Ipamorelin — and a short, cold, accountable chain of custody is how that purity survives the trip to your bench.

Walk the full synthesis pipeline

Handling, storage & why purity is hard

A physical mixture of two separately made peptides — Tesamorelin (a stabilized 44-residue GHRH analog) and Ipamorelin (a short pentapeptide secretagogue). Tesamorelin is the harder, longer synthesis of the two; the blend has no combined purity number, so a real certificate assays each peptide on its own and states the amount of each. Pooling a long and a short peptide in one solution also raises stability questions a single-peptide vial does not.

Storage
Store lyophilized, frozen, and protected from light; after reconstitution keep refrigerated and use within a short window. The longer GHRH analog is the more fragile component.
Handling
Reconstitute gently without vortexing. Read any certificate as two separate assays — identity, purity, and content for both the GHRH analog and the secretagogue — not one blended figure.

Don't judge a vial by its cake. A fluffy, good-looking lyophilized powder reflects bulking agents and freeze-drying parameters — not purity. Insist on a batch-specific certificate of analysis.

How peptides are made — the full pipeline

Research areas

  • Growth-hormone secretagogue research
  • Visceral adiposity
  • GH pulse amplification

Research-area guides

Frequently asked questions

What is Tesamorelin + Ipamorelin?+

A pairing of an FDA-approved GHRH analog (Tesamorelin) with a selective GH secretagogue (Ipamorelin), combining two receptor pathways to raise growth hormone.

Is the combination FDA-approved?+

No. Tesamorelin alone is approved for HIV-associated lipodystrophy; the combination with Ipamorelin has not been studied or approved as a blend.

How does it compare to CJC-1295 + Ipamorelin?+

Same two-receptor logic, but the GHRH component here (Tesamorelin) is a clinically approved, trial-backed analog rather than a research GHRH peptide.

Is it approved as a blend?+

No — only Tesamorelin as a single agent. This page is a research and educational reference.

Components

Tesamorelin + Ipamorelin is a blend. Each component is a single compound with its own catalog monograph — purity, mechanism, and research are documented per component below.

Related peptides

Peptide Agent

Ask the Agent about Tesamorelin + Ipamorelin

Dosing protocols, mechanism, comparisons, and the latest trials — citation-backed answers grounded in PubMed, PubChem, and ClinicalTrials.gov.